{"id":"W4200147408","doi":"10.1016/j.annonc.2021.10.018","title":"2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Oncology; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Distributed File System; Cancer; Immunotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002632952,0.0009045618,0.001392895,0.0003961817,0.0004820755,0.001462678,0.0009525991,0.00142709,0.00568132],"category_scores_gemma":[0.002261997,0.0005189142,0.002173947,0.0005045884,0.0007036894,0.001030291,0.000576242,0.002871997,0.000836213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009215478,"about_ca_system_score_gemma":0.001617655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001193587,"about_ca_topic_score_gemma":0.004012023,"domain_scores_codex":[0.9991181,0.0005091685,0.00003987276,0.0001068327,0.0001021228,0.0001239148],"domain_scores_gemma":[0.9986581,0.0003807446,0.0002727479,0.00008927562,0.0001167788,0.0004823424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8130028,0.009996475,0.05102437,0.001013424,0.003015933,0.0001145936,0.0001426325,0.001322546,0.01477843,0.0004364472,0.01068204,0.09447028],"study_design_scores_gemma":[0.5986242,0.2328365,0.1339021,0.0002148919,0.005252191,0.0003508619,0.0001356219,0.001860342,0.006973511,0.0006411971,0.01910546,0.0001031533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628505,0.006673433,0.0009910511,0.003391861,0.000637488,0.003060473,0.01737303,0.0001372986,0.004884877],"genre_scores_gemma":[0.9542676,0.002838512,0.005024727,0.003080269,0.0006224223,0.005812939,0.02143465,0.00008502905,0.006833908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00568132,"threshold_uncertainty_score":0.01900584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04314062178960634,"score_gpt":0.3874494096085126,"score_spread":0.3443087878189063,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}